IBD Associated With Increased Risk of Parkinson's Disease
TUESDAY, May 22, 2018 -- There is a significantly increased risk of Parkinson's disease (PD) in patients with inflammatory bowel disease (IBD), according to a study published online May 21 in Gut.
Marie Villumsen, Ph.D., from Bispebjerg and Frederiksberg Hospital in Copenhagen, Denmark, and colleagues used data from a nationwide population-based cohort study involving all individuals diagnosed with IBD in Denmark between 1977 and 2014 (76,477 participants) and non-IBD individuals (7,548,259 participants) who were comparable in terms of age, gender, and vital status. Comparisons were made between the groups for the incidence of PD and multiple system atrophy (MSA).
The researchers found that patients with IBD had a 22 percent increased risk of PD versus non-IBD individuals (hazard ratio, 1.22; 95 percent confidence interval, 1.09 to 1.35), which persisted regardless of age at IBD diagnosis, gender, or length of follow-up. The overall incidence of MSA was low, with a trend toward higher risk of MSA in patients with IBD versus non-IBD individuals (hazard ratio, 1.41; 95 percent confidence interval, 0.82 to 2.44). Furthermore, an increased risk of parkinsonism was seen in patients with ulcerative colitis (hazard ratio, 1.35; 95 percent confidence interval, 1.2 to 1.52) but not Crohn's disease (hazard ratio, 1.12; 95 percent confidence interval, 0.89 to 1.4).
"This nationwide, unselected, cohort study shows a significant association between IBD and later occurrence of PD, which is consistent with recent basic scientific findings of a potential role of gastrointestinal inflammation in development of parkinsonian disorders," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: May 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.